A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2023-02-05
AEs
3
Serious
1
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-05-19 (study day 92); relationship: not assessed
severe
serious
assessed
Grade 4 Anaemia — outcome: UNKNOWN; onset 2024-06-15 (study day 485); relationship: Y; serious criteria: life-threatening
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-07-05 (study day 505); relationship: not assessed
Data queries
No data queries.